Abbott is recalling a communication system that monitors heart failure patients implanted with its Heartmate 3 left ventricular assist device (LVAD) due to a risk that the system could unexpectedly ...
SAN DIEGO — Patients with advanced heart disease who received the HeartMate 3 left ventricular assist device had fewer clotting and bleeding events at 6 months than similar patients who received the ...
MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...
ST. PAUL, Minn.-- (BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the company has received an Innovation Award for its HeartMate 3 ™ Left ...
ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the company's HeartMate 3™ heart pump ...
When Dr. Robert Kormos, a cardiothoracic surgeon, began his career 30 years ago, he would dream of extending the lives of his patients who were often battling advanced heart failure. Now, as division ...
Newest HeartMate 3 LV Assist Device Slashes Thrombosis, Reoperation Rates in Advanced HF: MOMENTUM 3
ORLANDO, FL—The latest-generation HeartMate left ventricular assist device has beat out its predecessor with results so promising that at least one observer is raising the question of whether it’s ...
Good news for the HeartMate 3 (Abbott Cardiovascular) as a bridge to heart transplantation: in the 2 years following US Food and Drug Administration approval of the left ventricular assist device ...
ORLANDO -- The HeartMate 3 advantage appears durable to 2 years, with still no pump thrombosis requiring reoperation and fewer replacements or disabling strokes compared with the prior-generation ...
The FDA approved a new, less invasive surgical technique for the placement of Abbott’s best-selling heart pump, allowing patients to avoid open surgery. The HeartMate 3 left ventricular assist device ...
Cleveland, OH - Patients implanted with a HeartMate II (Thoratec) left ventricular assist device (LVAD) following its 2008 FDA approval have had similar outcomes to what was predicted by the ...
PLEASANTON, Calif., May 3, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback